271 related articles for article (PubMed ID: 18342360)
1. Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone.
Dean RL; Todtenkopf MS; Deaver DR; Arastu MF; Dong N; Reitano K; O'Driscoll K; Kriksciukaite K; Gastfriend DR
Pharmacol Biochem Behav; 2008 Jun; 89(4):515-22. PubMed ID: 18342360
[TBL] [Abstract][Full Text] [Related]
2. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
3. Influence of low doses of naltrexone on morphine antinociception and morphine tolerance in male and female rats of four strains.
Terner JM; Barrett AC; Lomas LM; Negus SS; Picker MJ
Pain; 2006 May; 122(1-2):90-101. PubMed ID: 16527399
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment.
O'Malley SS; Garbutt JC; Gastfriend DR; Dong Q; Kranzler HR
J Clin Psychopharmacol; 2007 Oct; 27(5):507-12. PubMed ID: 17873686
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain.
Webster LR; Brewer R; Wang C; Sekora D; Johnson FK; Morris D; Stauffer J
J Pain Symptom Manage; 2010 Nov; 40(5):734-46. PubMed ID: 21075272
[TBL] [Abstract][Full Text] [Related]
6. Opioid titration and conversion in patients receiving morphine sulfate and naltrexone hydrochloride extended release capsules.
Webster LR; Brewer R; Morris D; Cleveland JM; Setnik B
Postgrad Med; 2011 Sep; 123(5):155-64. PubMed ID: 21904098
[TBL] [Abstract][Full Text] [Related]
7. Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules.
Johnson FK; Ciric S; Boudriau S; Kisicki J; Stauffer J
J Clin Pharmacol; 2012 May; 52(5):747-56. PubMed ID: 21593282
[TBL] [Abstract][Full Text] [Related]
8. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
[TBL] [Abstract][Full Text] [Related]
9. Discrimination of a single dose of morphine followed by naltrexone: substitution of other agonists for morphine and other antagonists for naltrexone in a rat model of acute dependence.
Holtzman SG
J Pharmacol Exp Ther; 2003 Mar; 304(3):1033-41. PubMed ID: 12604679
[TBL] [Abstract][Full Text] [Related]
10. 6beta-naltrexol preferentially antagonizes opioid effects on gastrointestinal transit compared to antinociception in mice.
Yancey-Wrona JE; Raymond TJ; Mercer HK; Sadée W; Bilsky EJ
Life Sci; 2009 Sep; 85(11-12):413-20. PubMed ID: 19583969
[TBL] [Abstract][Full Text] [Related]
11. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients.
Setnik B; Roland CL; Goli V; Sommerville K; Webster L
J Opioid Manag; 2013; 9(2):139-50. PubMed ID: 23709323
[TBL] [Abstract][Full Text] [Related]
12. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
[TBL] [Abstract][Full Text] [Related]
13. Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone.
Fishman M
Addiction; 2008 Aug; 103(8):1399-401. PubMed ID: 18855831
[TBL] [Abstract][Full Text] [Related]
14. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
15. Influence of chronic prenatal and postnatal administration of naltrexone in locomotor activity induced by morphine in mice.
Medina Jiménez M; Luján Estrada M; Rodríguez R
Arch Med Res; 1997; 28(1):61-5. PubMed ID: 9078589
[TBL] [Abstract][Full Text] [Related]
16. A morphine/naltrexone combination (Embeda) for pain.
Med Lett Drugs Ther; 2010 Mar; 52(1334):22-3. PubMed ID: 20336033
[No Abstract] [Full Text] [Related]
17. The analgesic actions of centrally administered celecoxib are mediated by endogenous opioids.
Rezende RM; Dos Reis WG; Duarte ID; Lima PP; Bakhle YS; de Francischi JN
Pain; 2009 Mar; 142(1-2):94-100. PubMed ID: 19186002
[TBL] [Abstract][Full Text] [Related]
18. Analgesic activity and pharmacological characterization of N-[1-phenylpyrazol-3-yl]-N-[1-(2-phenethyl)-4-piperidyl] propenamide, a new opioid agonist acting peripherally.
Goicoechea C; Sánchez E; Cano C; Jagerovic N; Martín MI
Eur J Pharmacol; 2008 Oct; 595(1-3):22-9. PubMed ID: 18706410
[TBL] [Abstract][Full Text] [Related]
19. Acute and chronic fentanyl administration causes hyperalgesia independently of opioid receptor activity in mice.
Waxman AR; Arout C; Caldwell M; Dahan A; Kest B
Neurosci Lett; 2009 Oct; 462(1):68-72. PubMed ID: 19559072
[TBL] [Abstract][Full Text] [Related]
20. Antinociceptive and adverse effects of mu- and kappa-opioid receptor agonists: a comparison of morphine and U50488-H.
Gallantine EL; Meert TF
Basic Clin Pharmacol Toxicol; 2008 Nov; 103(5):419-27. PubMed ID: 18699797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
